109例早期非小细胞肺癌SABR预后分析

doi:10.3760/cma.j.cn113030-20200429-00226

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the long-term survival and identify prognostic factors of patients diagnosed with early-stage non-small cell lung cancer (ES-NSCLC) receiving stereotactic ablation radiotherapy (SABR). Methods Clinical data of 109 ES-NSCLC patients treated with SABR in Henan Cancer Hospital from 2011 to 2018 were retrospectively analyzed. The overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS) were calculated by Kaplan-Meier method and log-rank test. Multivariate prognostic analysis was performed by Cox regression model. Results The median follow-up time was 44 months (2-93 months). The median OS, CSS and PFS were 78 months, 78 months and 44 months, respectively. The 1-year OS, CSS and PFS were 95.4%, 97.2% and 84.1%, and 75.6%, 79.1% and 56.6% for the 3-year OS, CSS and PFS, and 55.6%, 60.7% and 37.3% for the 5-year OS, CSS and PFS, respectively. Univariate analysis showed that ECOG score, age, smoking history and derived-neutrophil/lymphocyte ratio (dNLR) were the influencing factors of OS (P=0.03, 0.02, 0.04, 0.001). Age, smoking history and dNLR were the influencing factors of CSS (P=0.02, 0.03, 0.001). Multivariate analysis demonstrated that dNLR was an independent prognostic factor for OS and CSS (P=0.001, 0.001). Conclusions ES-NSCLC patients treated with SABR can achieve favorable survival. The dNLR is an independent prognostic factor of OS and CSS, which can be considered in clinical application.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zheng Xiaoli
	Liu Meiling
	Wang Xiaohui
	Sun Yanan
	Song Shuai
	Yang Yang
	Jiao Ruidi
	Ye Ke
	Fan Chengcheng
	Ge Hong

Key words： Non-small cell lung cancer/stereotactic ablation radiotherapy Prognosis Derived-neutrophil-lymphocyte ratio

Received: 29 April 2020

Fund:Surface Project of National Natural Science Foundation of China (81373230)

Corresponding Authors: Ge Hong, Email:gehong666@126.com

Cite this article:

Zheng Xiaoli,Liu Meiling,Wang Xiaohui et al. Analysis of clinical outcomes and prognostic factors in 109 patients with early-stage non-small cell lung cancer treated with stereotactic ablation radiotherapy[J]. Chinese Journal of Radiation Oncology, 2020, 29(12): 1031-1036.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200429-00226 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I12/1031

[1] Landreneau RJ, Normolle DP, Christie NA, et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage Ⅰ non-small-cell lung cancer:a propensity-matched analysis[J]. J Clin Oncol, 2014, 32(23):2449-2455. DOI:10.1200/JCO.
[2] Luo H, Ge H, Cui Y, et al. Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy – a single center experience[J]. J Cancer, 2018,9(2):182-188. DOI:10.7150/jca.21703.
[3] Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage Ⅰ non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(9):1287-1288. DOI:10.1001/jamaoncol.
[4] Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer:NRG oncology/RTOG 0813 trial[J]. J Clin Oncol, 2019, 37(15):1316-1325. DOI:10.1200/jco.18.00622.
[5] Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):e299-303. DOI:10.1016/j.ijrobp.2011.01.038.
[6] Cox S, Hurt C, Grenader T, et al. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.[J]. Radiother Oncol, 2017,125(1):154-159. DOI:10.1016/j.radonc.
[7] Potters L, Kavanagh B, Galvin JM, et al. American society for therapeutic radiolog and oncology (ASTRO) and American college of radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2010, 76(2):326-332. DOI:10.1016/j.ijrobp.
[8] Haasbeek CJ, Lagerwaard FJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer[J]. J Thorac Oncol, 2011, 6(12):2036-2043. DOI:10.1097/JTO.0b013e31822e71d8.
[9] Hegi F, D'Souza M, Azzi M, et al. Comparing the outcomes of stereotactic ablative radiotherapy (SABR) and non-SABRdefinitive radiotherapy approaches to thoracic malignancy:a systematic review and meta-analysis[J]. Clin Lung Cancer, 2018, 19(3):199-212. DOI:10.1016/j.cllc.2017.11.006.
[10] Sun B, Brooks ED, Komaki RU,et al. 7-year follow-up outcomes after stereotactic ablation radiotherapy for stage Ⅰ NSCLC:results of a phase Ⅱ clinical trial[J]. Cancer, 2017, 123(16):3031-3039. DOI:10.1002/cncr.30693.
[11] Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperableT1N0M0 non-small cell lung cancer:Japan clinical oncology group study JCOG0403[J]. Int J Radiat Oncol Biol Phys, 2015, 93(5):989-996. DOI:10.1016/j.ijrobp.2015.07.2278.
[12] Onimaru R, Onishi H, Ogawa G, et al. Final report of survival and late toxicities in the phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)[J]. Jpn J Clin Oncol, 2018, 48(12):1076-1082. DOI:10.1093/jjco/hyy141.
[13] Videtic GM, Hu C, Singh AK, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer:nrg oncology RTOG 0915(NCCTG N0927)[J]. Int J Radiat Oncol Biol Phys, 2015, 93(4):757-764. DOI:10.1016/j.ijrobp.2015.07.2260.
[14] Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ non-small cell lung cancer:updated results of 257 patients in a Japanese multi-institutional study[J]. J Thorac Oncol, 2007, 2(1):S94-100. DOI:10.1097/JTO.0b013e318074〗de34.
[15] Hanahan D, Weinberg RA. The hallmarks of cancer[J]. Cell, 2000, 100(1):57-70. DOI:10.1016/S0092-8674(00)81683-9.
[16] Shaverdian N, Veruttipong D, Wang J, et al. Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy[J]. Clin Lung Cancer, 2016, 17(1):39-46. DOI:10.1016/j.cllc.2015.07.007.
[17] Dovedi SJ, Cheadle EJ, Popple A, et al. Fractionated radiation therapy stimulates anti-tumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD1 blockade[J]. Clin Cancer Res, 2017, 23(18):5514-5526. DOI:10.1158/1078-0432.